Study to Evaluate the Efficacy of the décoLITE LED Device in Treating the Signs of Skin Aging of the décolletage Area

August 4, 2024 updated by: Steven Baker
To assess the efficacy of the décoLITE LED system in reducing the signs of skin aging of the décolletage area one week after a six-week treatment course.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This was an open-label, single-center trial. Subjects carried out 5 treatments on separate days each week for 6 weeks. The plan for the study was to recruit 25 subjects to consider any dropouts to arrive at a final study total of 20.

Treatments were of 10 minutes duration using a combination of red (630nm) and near infrared (830nm) emitted from light emitting diodes. The device emitted 30mW/cm2 of light, delivering a dose of 18J/cm2 per treatment.

Subjects were assessed at baseline, at 5 weeks, and at 7 weeks (one week after the last treatment).

Assessments included separate evaluations of lines and pigment of the décolletage using the validated scale developed by Landau et al. by the principal investigator and a third party blinded physician, standardized photography, and recording of safety incidents. Subjective responses were based on treatment efficacy and ease of use of the device.

Study Type

Interventional

Enrollment (Actual)

18

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Sutton Coldfield, United Kingdom, B742UG
        • Suite A, Astor House

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy female, 30 to 65 years of age.
  • Fitzpatrick phototype I-VI skin.
  • Gave written informed consent.
  • Photoaging of the décolletage area.
  • Agreed NOT to use anti-aging products that contain active ingredients such as retinol and glycolic acid on the treatment area during the study period.
  • Agreed NOT to undergo any aesthetic treatments (such as chemical peels, microdermabrasion, laser surfacing, etc.) in the treatment area during the study period

Exclusion Criteria:

  • Suffering from a systemic photosensitive disorder such as Lupus erythematosus, photosensitive eczema, or Albinism.
  • Currently taking (or with a history of taking) medication that is known to induce photosensitivity.
  • Having known malignancy and/or undergoing chemotherapy, radiotherapy, or high doses of corticosteroids.
  • Suffering from keloid scars or birth marks in the treatment area.
  • Suffering from eczema, psoriasis, or skin rashes in the treatment area.
  • Had used an anti-aging product within the 4 weeks prior to commencing the study.
  • Underwent plastic surgery within the last 6 months.
  • Pregnant, breast-feeding, or wishing to become pregnant during the study period.
  • Being enrolled in another clinical trial during the same study period.
  • Having a planned hospital admission and/or surgical procedure for an illness or disease which existed before enrollment into the clinical trial, and which may interfere with the course or outcome of the study.
  • Having medical or psychological condition(s) associated with a risk of poor protocol compliance (e.g., alcoholism or drug abuse).
  • Undergoing or is likely to undergo other treatments of the décolletage area.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active Light treatment Arm
Treatment with red and near infra red light 5 x week for 6 weeks
Red/Near infra red light therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction in chest lines at rest
Time Frame: 7 weeks after first treatment intervention
Reduction in chest lines at rest according to the validated Merz aesthetics décolleté grading scale developed by Landau, et al (2016).
7 weeks after first treatment intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction in chest pigmentation
Time Frame: 7 weeks after first treatment intervention
Reduction in chest pigmentation according to the validated Merz aesthetics décolleté grading scale developed by Landau, et al (2016
7 weeks after first treatment intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 24, 2020

Primary Completion (Actual)

December 4, 2020

Study Completion (Actual)

January 31, 2021

Study Registration Dates

First Submitted

July 31, 2024

First Submitted That Met QC Criteria

August 4, 2024

First Posted (Actual)

August 7, 2024

Study Record Updates

Last Update Posted (Actual)

August 7, 2024

Last Update Submitted That Met QC Criteria

August 4, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • DOC-5574 1/15/19

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No plan to share- confidential regulatory data

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Wrinkle

Subscribe